Public investors’ search for the next hot biotechnology acquisition target is helping even early-stage drugmakers to go public. Last year, several startups with drugs in the earliest phase of clinical trials—and some with treatments still only in lab testing—listed on the Nasdaq to capitalize on the hot biotech market. That trend continues...

Source: Wall Street Journal May 03, 2019 23:03 UTC